ID   APOA1_HUMAN             Reviewed;         267 AA.
AC   P02647; A8K866; Q6LDN9; Q6Q785; Q9UCS8; Q9UCT8;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   10-MAY-2017, entry version 224.
DE   RecName: Full=Apolipoprotein A-I;
DE            Short=Apo-AI;
DE            Short=ApoA-I;
DE   AltName: Full=Apolipoprotein A1;
DE   Contains:
DE     RecName: Full=Proapolipoprotein A-I;
DE              Short=ProapoA-I;
DE   Contains:
DE     RecName: Full=Truncated apolipoprotein A-I;
DE     AltName: Full=Apolipoprotein A-I(1-242);
DE   Flags: Precursor;
GN   Name=APOA1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6406984; DOI=10.1093/nar/11.9.2827;
RA   Shoulders C.C., Kornblihtt A.R., Munro B.S., Baralle F.E.;
RT   "Gene structure of human apolipoprotein A1.";
RL   Nucleic Acids Res. 11:2827-2837(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6304641; DOI=10.1093/nar/11.11.3703;
RA   Cheung P., Chan L.;
RT   "Nucleotide sequence of cloned cDNA of human apolipoprotein A-I.";
RL   Nucleic Acids Res. 11:3703-3715(1983).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6413973; DOI=10.1073/pnas.80.20.6147;
RA   Karathanasis S.K., Zannis V.I., Breslow J.L.;
RT   "Isolation and characterization of the human apolipoprotein A-I
RT   gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:6147-6151(1983).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6207999; DOI=10.1089/dna.1.1984.3.309;
RA   Seilhamer J.J., Protter A.A., Frossard P., Levy-Wilson B.;
RT   "Isolation and DNA sequence of full-length cDNA and of the entire gene
RT   for human apolipoprotein AI -- discovery of a new genetic polymorphism
RT   in the apo AI gene.";
RL   DNA 3:309-317(1984).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6328445; DOI=10.1093/nar/12.9.3917;
RA   Sharpe C.R., Sidoli A., Shelley C.S., Lucero M.A., Shoulders C.C.,
RA   Baralle F.E.;
RT   "Human apolipoproteins AI, AII, CII and CIII. cDNA sequences and mRNA
RT   abundance.";
RL   Nucleic Acids Res. 12:3917-3932(1984).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6198645; DOI=10.1073/pnas.81.1.66;
RA   Law S.W., Brewer H.B. Jr.;
RT   "Nucleotide sequence and the encoded amino acids of human
RT   apolipoprotein A-I mRNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:66-70(1984).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2995392;
RA   Law S.W., Brewer H.B. Jr.;
RT   "Tangier disease. The complete mRNA sequence encoding for preproapo-A-
RT   I.";
RL   J. Biol. Chem. 260:12810-12814(1985).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (VARIANT TANGIER).
RX   PubMed=3129297; DOI=10.1111/j.1432-1033.1988.tb14022.x;
RA   Makrides S.C., Ruiz-Opazo N., Hayden M.R., Nussbaum A.L.,
RA   Breslow J.L., Zannis V.I.;
RT   "Sequence and expression of Tangier apoA-I gene.";
RL   Eur. J. Biochem. 173:465-471(1988).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2673706; DOI=10.1089/dna.1.1989.8.429;
RA   Moguilevsky N., Roobol C., Loriau R., Guillaume J.P., Jacobs P.,
RA   Cravador A., Herzog A., Brouwers L., Scarso A., Gilles P.,
RA   Holmquist L., Carlson L.A., Bollen A.;
RT   "Production of human recombinant proapolipoprotein A-I in Escherichia
RT   coli: purification and biochemical characterization.";
RL   DNA 8:429-436(1989).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT THR-61.
RX   PubMed=15108119; DOI=10.1007/s00439-004-1106-x;
RA   Fullerton S.M., Buchanan A.V., Sonpar V.A., Taylor S.L., Smith J.D.,
RA   Carlson C.S., Salomaa V., Stengaard J.H., Boerwinkle E., Clark A.G.,
RA   Nickerson D.A., Weiss K.M.;
RT   "The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster.";
RL   Hum. Genet. 115:36-56(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Bollen A., Gobert J., Wuelfert E.;
RT   "Expression of human proapolipoprotein A-1.";
RL   Patent number EP0293357, 30-NOV-1988.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [16]
RP   PROTEIN SEQUENCE OF 19-27.
RX   PubMed=6409108; DOI=10.1016/0006-291X(83)91772-2;
RA   Brewer H.B. Jr., Fairwell T., Kay L., Meng M., Ronan R., Law S.,
RA   Light J.A.;
RT   "Human plasma proapoA-I: isolation and amino-terminal sequence.";
RL   Biochem. Biophys. Res. Commun. 113:626-632(1983).
RN   [17]
RP   PROTEIN SEQUENCE OF 25-267.
RX   PubMed=164450;
RA   Baker H.N., Gotto A.M. Jr., Jackson R.L.;
RT   "The primary structure of human plasma high density apolipoprotein
RT   glutamine I (ApoA-I). II. The amino acid sequence and alignment of
RT   cyanogen bromide fragments IV, III, and I.";
RL   J. Biol. Chem. 250:2725-2738(1975).
RN   [18]
RP   PROTEIN SEQUENCE OF 25-267.
RX   PubMed=204308; DOI=10.1016/0006-291X(78)91614-5;
RA   Brewer H.B. Jr., Fairwell T., Larue A., Ronan R., Houser A.,
RA   Bronzert T.J.;
RT   "The amino acid sequence of human APOA-I, an apolipoprotein isolated
RT   from high density lipoproteins.";
RL   Biochem. Biophys. Res. Commun. 80:623-630(1978).
RN   [19]
RP   PROTEIN SEQUENCE OF 25-56.
RX   PubMed=3047170; DOI=10.1172/JCI113682;
RA   Yui Y., Aoyama T., Morishita H., Takahashi M., Takatsu Y., Kawai C.;
RT   "Serum prostacyclin stabilizing factor is identical to apolipoprotein
RT   A-I (Apo A-I). A novel function of Apo A-I.";
RL   J. Clin. Invest. 82:803-807(1988).
RN   [20]
RP   PROTEIN SEQUENCE OF 25-50, FUNCTION, AND IDENTIFICATION IN THE SPAP
RP   COMPLEX.
RC   TISSUE=Serum;
RX   PubMed=1909888; DOI=10.1021/bi00101a011;
RA   Aakerloef E., Joernvall H., Slotte H., Pousette A.;
RT   "Identification of apolipoprotein A1 and immunoglobulin as components
RT   of a serum complex that mediates activation of human sperm motility.";
RL   Biochemistry 30:8986-8990(1991).
RN   [21]
RP   PROTEIN SEQUENCE OF 25-48.
RX   PubMed=2506184;
RA   Manjunath P., Marcel Y.L., Uma J., Seidah N.G., Chretien M.,
RA   Chapdelaine A.;
RT   "Apolipoprotein A-I binds to a family of bovine seminal plasma
RT   proteins.";
RL   J. Biol. Chem. 264:16853-16857(1989).
RN   [22]
RP   PROTEIN SEQUENCE OF 25-43.
RX   PubMed=3120314; DOI=10.1126/science.3120314;
RA   Prioli R.P., Ordovas J.M., Rosenberg I., Schaeffer E.J.,
RA   Pereira M.E.A.;
RT   "Similarity of cruzin, an inhibitor of Trypanosoma cruzi
RT   neuraminidase, to high-density lipoprotein.";
RL   Science 238:1417-1419(1987).
RN   [23]
RP   PROTEIN SEQUENCE OF 25-42.
RC   TISSUE=Heart;
RX   PubMed=7895732; DOI=10.1002/elps.11501501209;
RA   Corbett J.M., Wheeler C.H., Baker C.S., Yacoub M.H., Dunn M.J.;
RT   "The human myocardial two-dimensional gel protein database: update
RT   1994.";
RL   Electrophoresis 15:1459-1465(1994).
RN   [24]
RP   PROTEIN SEQUENCE OF 25-34.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [25]
RP   PROTEIN SEQUENCE OF 25-33, AND INTERACTION WITH APOA1BP AND CLU.
RX   PubMed=1742316; DOI=10.1016/0005-2760(91)90167-G;
RA   Ehnholm C., Bozas S.E., Tenkanen H., Kirszbaum L., Metso J.,
RA   Murphy B., Walker I.D.;
RT   "The apolipoprotein A-I binding protein of placenta and the SP-40,40
RT   protein of human blood are different proteins which both bind to
RT   apolipoprotein A-I.";
RL   Biochim. Biophys. Acta 1086:255-260(1991).
RN   [26]
RP   PROTEIN SEQUENCE OF 35-64; 70-101; 121-140; 165-173; 185-195 AND
RP   240-263, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [27]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 118-267.
RX   PubMed=6294659; DOI=10.1073/pnas.79.22.6861;
RA   Breslow J.L., Ross D., McPherson J., Williams H.W., Kurnit D.,
RA   Nussbaum A.L., Karathanasis S.K., Zannis V.I.;
RT   "Isolation and characterization of cDNA clones for human
RT   apolipoprotein A-I.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:6861-6865(1982).
RN   [28]
RP   PALMITOYLATION.
RX   PubMed=3005308;
RA   Hoeg J.M., Meng M.S., Ronan R., Fairwell T., Brewer H.B. Jr.;
RT   "Human apolipoprotein A-I. Post-translational modification by fatty
RT   acid acylation.";
RL   J. Biol. Chem. 261:3911-3914(1986).
RN   [29]
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=6405383; DOI=10.1073/pnas.80.9.2574;
RA   Zannis V.I., Karathanasis S.K., Keutmann H.T., Goldberger G.,
RA   Breslow J.L.;
RT   "Intracellular and extracellular processing of human apolipoprotein A-
RT   I: secreted apolipoprotein A-I isoprotein 2 is a propeptide.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:2574-2578(1983).
RN   [30]
RP   GLYCATION AT LYS-263.
RX   PubMed=8261628; DOI=10.1016/0009-8981(93)90165-Z;
RA   Calvo C., Ulloa N., Campos M., Verdugo C., Ayrault-Jarrier M.;
RT   "The preferential site of non-enzymatic glycation of human
RT   apolipoprotein A-I in vivo.";
RL   Clin. Chim. Acta 217:193-198(1993).
RN   [31]
RP   INTERACTION WITH APOA1BP.
RX   PubMed=11991719; DOI=10.1006/geno.2002.6761;
RA   Ritter M., Buechler C., Boettcher A., Barlage S., Schmitz-Madry A.,
RA   Orso E., Bared S.M., Schmiedeknecht G., Baehr C.H., Fricker G.,
RA   Schmitz G.;
RT   "Cloning and characterization of a novel apolipoprotein A-I-binding
RT   protein, AI-BP, secreted by cells of the kidney proximal tubules in
RT   response to HDL or ApoA-I.";
RL   Genomics 79:693-702(2002).
RN   [32]
RP   MASS SPECTROMETRY, OXIDATION AT MET-110 AND MET-136, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=12576517; DOI=10.1194/jlr.M200256-JLR200;
RA   Pankhurst G., Wang X.L., Wilcken D.E., Baernthaler G., Panzenboeck U.,
RA   Raftery M., Stocker R.;
RT   "Characterization of specifically oxidized apolipoproteins in mildly
RT   oxidized high density lipoprotein.";
RL   J. Lipid Res. 44:349-355(2003).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12562854; DOI=10.1194/jlr.D200034-JLR200;
RA   Niederkofler E.E., Tubbs K.A., Kiernan U.A., Nedelkov D., Nelson R.W.;
RT   "Novel mass spectrometric immunoassays for the rapid structural
RT   characterization of plasma apolipoproteins.";
RL   J. Lipid Res. 44:630-639(2003).
RN   [34]
RP   INTERACTION WITH NDRG1.
RX   PubMed=15922294; DOI=10.1016/j.bbrc.2005.05.050;
RA   Hunter M., Angelicheva D., Tournev I., Ingley E., Chan D.C.,
RA   Watts G.F., Kremensky I., Kalaydjieva L.;
RT   "NDRG1 interacts with APO A-I and A-II and is a functional candidate
RT   for the HDL-C QTL on 8q24.";
RL   Biochem. Biophys. Res. Commun. 332:982-992(2005).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [37]
RP   CHARACTERIZATION OF VARIANT MILANO CYS-197.
RX   PubMed=24755625; DOI=10.1371/journal.pone.0096150;
RA   Petrlova J., Dalla-Riva J., Morgelin M., Lindahl M., Krupinska E.,
RA   Stenkula K.G., Voss J.C., Lagerstedt J.O.;
RT   "Secondary structure changes in ApoA-I Milano (R173C) are not
RT   accompanied by a decrease in protein stability or solubility.";
RL   PLoS ONE 9:E96150-E96150(2014).
RN   [38]
RP   STRUCTURE BY NMR OF 190-209.
RX   PubMed=8664326; DOI=10.1016/0005-2760(96)00037-9;
RA   Wang G., Treleaven W.D., Cushley R.J.;
RT   "Conformation of human serum apolipoprotein A-I(166-185) in the
RT   presence of sodium dodecyl sulfate or dodecylphosphocholine by 1H-NMR
RT   and CD. Evidence for specific peptide-SDS interactions.";
RL   Biochim. Biophys. Acta 1301:174-184(1996).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (4.0 ANGSTROMS) OF 67-267.
RX   PubMed=9356442; DOI=10.1073/pnas.94.23.12291;
RA   Borhani D.W., Rogers D.P., Engler J.A., Brouillette C.G.;
RT   "Crystal structure of truncated human apolipoprotein A-I suggests a
RT   lipid-bound conformation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:12291-12296(1997).
RN   [40]
RP   DISEASE.
RX   PubMed=8240372; DOI=10.1006/bbrc.1993.2341;
RA   Nakata K., Kobayashi K., Yanagi H., Shimakura Y., Tsuchiya S.,
RA   Arinami T., Hamaguchi H.;
RT   "Autosomal dominant hypoalphalipoproteinemia due to a completely
RT   defective apolipoprotein A-I gene.";
RL   Biochem. Biophys. Res. Commun. 196:950-955(1993).
RN   [41]
RP   DISEASE.
RX   PubMed=8282791; DOI=10.1172/JCI116949;
RA   Ng D.S., Leiter L.A., Vezina C., Connelly P.W., Hegele R.A.;
RT   "Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I
RT   deficiency in a family with analphalipoproteinemia.";
RL   J. Clin. Invest. 93:223-229(1994).
RN   [42]
RP   VARIANT MILANO CYS-197.
RX   PubMed=6401735;
RA   Weisgraber K.H., Rall S.C. Jr., Bersot T.P., Mahley R.W.,
RA   Franceschini G., Sirtori C.R.;
RT   "Apolipoprotein A-IMilano. Detection of normal A-I in affected
RT   subjects and evidence for a cysteine for arginine substitution in the
RT   variant A-I.";
RL   J. Biol. Chem. 258:2508-2513(1983).
RN   [43]
RP   VARIANT TANGIER.
RX   PubMed=6412234; DOI=10.1073/pnas.80.19.6081;
RA   Schmitz G., Assmann G., Rall S.C. Jr., Mahley R.W.;
RT   "Tangier disease: defective recombination of a specific Tangier
RT   apolipoprotein A-I isoform (pro-apo A-I) with high density
RT   lipoproteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:6081-6085(1983).
RN   [44]
RP   VARIANT GIESSEN ARG-167.
RX   PubMed=6489332; DOI=10.1111/j.1432-1033.1984.tb08467.x;
RA   Utermann G., Haas J., Steinmetz A., Paetzold R., Rall S.C. Jr.,
RA   Weisgraber K.H., Mahley R.W.;
RT   "Apolipoprotein A-IGiessen (Pro143-->Arg). A mutant that is defective
RT   in activating lecithin:cholesterol acyltransferase.";
RL   Eur. J. Biochem. 144:325-331(1984).
RN   [45]
RP   VARIANT NORWAY LYS-160.
RX   PubMed=6432779;
RA   Rall S.C. Jr., Weisgraber K.H., Mahley R.W., Ogawa Y., Fielding C.J.,
RA   Utermann G., Haas J., Steinmetz A., Menzel H.J., Assmann G.;
RT   "Abnormal lecithin:cholesterol acyltransferase activation by a human
RT   apolipoprotein A-I variant in which a single lysine residue is
RT   deleted.";
RL   J. Biol. Chem. 259:10063-10070(1984).
RN   [46]
RP   PROTEIN SEQUENCE OF 25-107, AND VARIANT AMYL8 ARG-50.
RX   PubMed=3142462; DOI=10.1016/S0006-291X(88)80909-4;
RA   Nichols W.C., Dwulet F.E., Liepnieks J., Benson M.D.;
RT   "Variant apolipoprotein AI as a major constituent of a human
RT   hereditary amyloid.";
RL   Biochem. Biophys. Res. Commun. 156:762-768(1988).
RN   [47]
RP   VARIANT AMYL8 ARG-50.
RX   PubMed=2123470; DOI=10.1016/0888-7543(90)90288-6;
RA   Nichols W.C., Gregg R.E., Brewer H.B. Jr., Benson M.D.;
RT   "A mutation in apolipoprotein A-I in the Iowa type of familial
RT   amyloidotic polyneuropathy.";
RL   Genomics 8:318-323(1990).
RN   [48]
RP   PROTEIN SEQUENCE OF 25-267, AND VARIANT FUKUOKA LYS-134.
RX   PubMed=2107878; DOI=10.1016/0005-2760(90)90292-6;
RA   Takada Y., Sasaki J., Ogata S., Nakanishi T., Ikehara Y., Arakawa K.;
RT   "Isolation and characterization of human apolipoprotein A-I Fukuoka
RT   (110 Glu-->Lys). A novel apolipoprotein variant.";
RL   Biochim. Biophys. Acta 1043:169-176(1990).
RN   [49]
RP   PROTEIN SEQUENCE OF 25-112, AND VARIANT AMYL8 ARG-84.
RX   PubMed=1502149; DOI=10.1073/pnas.89.16.7389;
RA   Soutar A.K., Hawkins P.N., Vigushin D.M., Tennent G.A., Booth S.E.,
RA   Hutton T., Nguyen O., Totty N.F., Feest T.G., Hsuan J.J., Pepys M.B.;
RT   "Apolipoprotein AI mutation Arg-60 causes autosomal dominant
RT   amyloidosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:7389-7393(1992).
RN   [50]
RP   VARIANT BALTIMORE LEU-34.
RX   PubMed=2108924; DOI=10.1007/BF00195816;
RA   Ladias J.A.A., Kwiterovich P.O. Jr., Smith H.H., Karathanasis S.K.,
RA   Antonarakis S.E.;
RT   "Apolipoprotein A1 Baltimore (Arg-10-->Leu), a new ApoA1 variant.";
RL   Hum. Genet. 84:439-445(1990).
RN   [51]
RP   VARIANTS ARG-27; ARG-28 AND ARG-189.
RX   PubMed=2512329; DOI=10.1172/JCI114355;
RA   von Eckardstein A., Funke H., Henke A., Altland K., Benninghoven A.,
RA   Assmann G., Welp S., Roetrige A., Kock R.;
RT   "Apolipoprotein A-I variants. Naturally occurring substitutions of
RT   proline residues affect plasma concentration of apolipoprotein A-I.";
RL   J. Clin. Invest. 84:1722-1730(1989).
RN   [52]
RP   VARIANTS GLU-113; MET-131; GLY-163; VAL-171 AND LYS-222.
RX   PubMed=2111322;
RA   von Eckardstein A., Funke H., Walter M., Altland K., Benninghoven A.,
RA   Assmann G.;
RT   "Structural analysis of human apolipoprotein A-I variants. Amino acid
RT   substitutions are nonrandomly distributed throughout the
RT   apolipoprotein A-I primary structure.";
RL   J. Biol. Chem. 265:8610-8617(1990).
RN   [53]
RP   VARIANTS HITA AND TSUSHIMA.
RX   PubMed=7918609;
RA   Araki K., Sasaki J., Matsunaga A., Takada Y., Moriyama K., Hidaka K.,
RA   Arakawa K.;
RT   "Characterization of two new human apolipoprotein A-I variants:
RT   apolipoprotein A-I Tsushima (Trp-108-->Arg) and A-I Hita (Ala-
RT   95-->Asp).";
RL   Biochim. Biophys. Acta 1214:272-278(1994).
RN   [54]
RP   VARIANT AMYL8 ARG-50.
RX   PubMed=8208902;
RA   Vigushin D.M., Gough J., Allan D., Alguacil A., Penner B.,
RA   Pettigrew N.M., Quinonez G., Bernstein K., Booth S.E., Booth D.R.,
RA   Soutar A.K., Hawkins P.N., Pepys M.B.;
RT   "Familial nephropathic systemic amyloidosis caused by apolipoprotein
RT   AI variant Arg26.";
RL   Q. J. Med. 87:149-154(1994).
RN   [55]
RP   VARIANT AOITA GLU-180.
RX   PubMed=9514407; DOI=10.1161/01.ATV.18.3.389;
RA   Huang W., Sasaki J., Matsunaga A., Nanimatsu H., Moriyama K., Han H.,
RA   Kugi M., Koga T., Yamaguchi K., Arakawa K.;
RT   "A novel homozygous missense mutation in the apo A-I gene with apo A-I
RT   deficiency.";
RL   Arterioscler. Thromb. Vasc. Biol. 18:389-396(1998).
RN   [56]
RP   VARIANT ZARAGOZA ARG-168.
RA   Recalde D., Cenarro A., Civeira F., Pocovi M.;
RT   "Apo A-I Zaragoza(L144R): a novel mutation in the apolipoprotein A-I
RT   gene associated with familial hypoalphalipoproteinemia.";
RL   Hum. Mutat. 11:416-416(1998).
RN   [57]
RP   VARIANT ILE-92.
RX   PubMed=12966036; DOI=10.1093/hmg/ddg314;
RA   Morabia A., Cayanis E., Costanza M.C., Ross B.M., Flaherty M.S.,
RA   Alvin G.B., Das K., Gilliam T.C.;
RT   "Association of extreme blood lipid profile phenotypic variation with
RT   11 reverse cholesterol transport genes and 10 non-genetic
RT   cardiovascular disease risk factors.";
RL   Hum. Mol. Genet. 12:2733-2743(2003).
RN   [58]
RP   VARIANT ILE-92, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22028381; DOI=10.1093/jmcb/mjr024;
RA   Su Z.D., Sun L., Yu D.X., Li R.X., Li H.X., Yu Z.J., Sheng Q.H.,
RA   Lin X., Zeng R., Wu J.R.;
RT   "Quantitative detection of single amino acid polymorphisms by targeted
RT   proteomics.";
RL   J. Mol. Cell Biol. 3:309-315(2011).
RN   [59]
RP   VARIANT BOSTON SER-173.
RX   PubMed=26073399; DOI=10.1016/j.jacl.2015.02.005;
RA   Anthanont P., Asztalos B.F., Polisecki E., Zachariah B.,
RA   Schaefer E.J.;
RT   "Case report: A novel apolipoprotein A-I missense mutation apoA-I
RT   (Arg149Ser)Boston associated with decreased lecithin-cholesterol
RT   acyltransferase activation and cellular cholesterol efflux.";
RL   J. Clin. Lipidol. 9:390-395(2015).
CC   -!- FUNCTION: Participates in the reverse transport of cholesterol
CC       from tissues to the liver for excretion by promoting cholesterol
CC       efflux from tissues and by acting as a cofactor for the lecithin
CC       cholesterol acyltransferase (LCAT). As part of the SPAP complex,
CC       activates spermatozoa motility. {ECO:0000269|PubMed:1909888}.
CC   -!- SUBUNIT: Interacts with APOA1BP and CLU. Component of a sperm
CC       activating protein complex (SPAP), consisting of APOA1, an
CC       immunoglobulin heavy chain, an immunoglobulin light chain and
CC       albumin. Interacts with NDRG1. {ECO:0000269|PubMed:11991719,
CC       ECO:0000269|PubMed:15922294, ECO:0000269|PubMed:1742316,
CC       ECO:0000269|PubMed:1909888}.
CC   -!- INTERACTION:
CC       Self; NbExp=14; IntAct=EBI-701692, EBI-701692;
CC       O95477:ABCA1; NbExp=4; IntAct=EBI-701692, EBI-784112;
CC       P05067:APP; NbExp=5; IntAct=EBI-701692, EBI-77613;
CC       Q96DZ9:CMTM5; NbExp=3; IntAct=EBI-701692, EBI-2548702;
CC       Q96DZ9-2:CMTM5; NbExp=5; IntAct=EBI-701692, EBI-11522780;
CC       P02671:FGA; NbExp=2; IntAct=EBI-701692, EBI-348571;
CC       P00738:HP; NbExp=3; IntAct=EBI-701692, EBI-1220767;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Major protein of plasma HDL, also found in
CC       chylomicrons. Synthesized in the liver and small intestine. The
CC       oxidized form at Met-110 and Met-136 is increased in individuals
CC       with increased risk for coronary artery disease, such as in
CC       carrier of the eNOSa/b genotype and exposure to cigarette smoking.
CC       It is also present in increased levels in aortic lesions relative
CC       to native ApoA-I and increased levels are seen with increasing
CC       severity of disease. {ECO:0000269|PubMed:12576517}.
CC   -!- PTM: Glycosylated. {ECO:0000250}.
CC   -!- PTM: Palmitoylated. {ECO:0000269|PubMed:3005308}.
CC   -!- PTM: Phosphorylation sites are present in the extracellular
CC       medium.
CC   -!- MASS SPECTROMETRY: Mass=28081; Method=Electrospray; Range=25-267;
CC       Note=Without methionine sulfoxide.;
CC       Evidence={ECO:0000269|PubMed:12576517};
CC   -!- MASS SPECTROMETRY: Mass=28098; Method=Electrospray; Range=25-267;
CC       Note=With 1 methionine sulfoxide, oxidation at Met-110.;
CC       Evidence={ECO:0000269|PubMed:12576517};
CC   -!- MASS SPECTROMETRY: Mass=28095; Method=Electrospray; Range=25-267;
CC       Note=With 1 methionine sulfoxide, oxidation at Met-136.;
CC       Evidence={ECO:0000269|PubMed:12576517};
CC   -!- MASS SPECTROMETRY: Mass=28114; Method=Electrospray; Range=25-267;
CC       Note=With 2 methionine sulfoxides, oxidation at Met-110 and Met-
CC       136.; Evidence={ECO:0000269|PubMed:12576517};
CC   -!- POLYMORPHISM: Genetic variations in APOA1 can result in APOA1
CC       deficiency and are associated with low levels of HDL cholesterol
CC       [MIM:107680]. {ECO:0000305}.
CC   -!- DISEASE: High density lipoprotein deficiency 2 (HDLD2)
CC       [MIM:604091]: Inherited as autosomal dominant trait. It is
CC       characterized by moderately low HDL cholesterol, predilection
CC       toward premature coronary artery disease (CAD) and a reduction in
CC       cellular cholesterol efflux. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: High density lipoprotein deficiency 1 (HDLD1)
CC       [MIM:205400]: Recessive disorder characterized by absence of high
CC       density lipoprotein (HDL) cholesterol from plasma, accumulation of
CC       cholesteryl esters, premature coronary artery disease (CAD),
CC       hepatosplenomegaly, recurrent peripheral neuropathy and
CC       progressive muscle wasting and weakness. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=APOA1 mutations may be involved in the pathogenesis
CC       of amyloid polyneuropathy-nephropathy Iowa type, also known as
CC       amyloidosis van Allen type or familial amyloid polyneuropathy type
CC       III (PubMed:3142462 and PubMed:2123470). The clinical picture is
CC       dominated by neuropathy in the early stages of the disease and
CC       nephropathy late in the course. Death is due in most cases to
CC       renal amyloidosis.
CC   -!- DISEASE: Amyloidosis 8 (AMYL8) [MIM:105200]: A form of hereditary
CC       generalized amyloidosis. Clinical features include extensive
CC       visceral amyloid deposits, renal amyloidosis resulting in
CC       nephrotic syndrome, arterial hypertension, hepatosplenomegaly,
CC       cholestasis, petechial skin rash. There is no involvement of the
CC       nervous system. {ECO:0000269|PubMed:1502149,
CC       ECO:0000269|PubMed:2123470, ECO:0000269|PubMed:3142462,
CC       ECO:0000269|PubMed:8208902}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the apolipoprotein A1/A4/E family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=APOA1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J00098; AAB59514.1; -; Genomic_DNA.
DR   EMBL; X01038; CAA25519.1; -; Genomic_DNA.
DR   EMBL; X02162; CAA26097.1; -; mRNA.
DR   EMBL; X00566; CAA25232.1; -; mRNA.
DR   EMBL; M11791; AAA35545.1; -; mRNA.
DR   EMBL; X07496; CAA30377.1; -; Genomic_DNA.
DR   EMBL; M27875; AAA62829.1; -; mRNA.
DR   EMBL; M29068; AAA51747.1; -; mRNA.
DR   EMBL; AY422952; AAQ91811.1; -; Genomic_DNA.
DR   EMBL; AY555191; AAS68227.1; -; Genomic_DNA.
DR   EMBL; A14829; CAA01198.1; -; mRNA.
DR   EMBL; AK292231; BAF84920.1; -; mRNA.
DR   EMBL; EF444948; ACA05932.1; -; Genomic_DNA.
DR   EMBL; EF444948; ACA05933.1; -; Genomic_DNA.
DR   EMBL; EF444948; ACA05934.1; -; Genomic_DNA.
DR   EMBL; EF444948; ACA05935.1; -; Genomic_DNA.
DR   EMBL; EF444948; ACA05936.1; -; Genomic_DNA.
DR   EMBL; CH471065; EAW67274.1; -; Genomic_DNA.
DR   EMBL; BC005380; AAH05380.1; -; mRNA.
DR   EMBL; BC110286; AAI10287.1; -; mRNA.
DR   CCDS; CCDS8378.1; -.
DR   PIR; A90947; LPHUA1.
DR   RefSeq; NP_000030.1; NM_000039.2.
DR   RefSeq; NP_001304946.1; NM_001318017.1.
DR   RefSeq; NP_001304947.1; NM_001318018.1.
DR   RefSeq; NP_001304950.1; NM_001318021.1.
DR   UniGene; Hs.93194; -.
DR   PDB; 1AV1; X-ray; 4.00 A; A/B/C/D=68-267.
DR   PDB; 1GW3; NMR; -; A=166-211.
DR   PDB; 1GW4; NMR; -; A=166-211.
DR   PDB; 1ODP; NMR; -; A=190-209.
DR   PDB; 1ODQ; NMR; -; A=190-209.
DR   PDB; 1ODR; NMR; -; A=190-209.
DR   PDB; 2A01; X-ray; 2.40 A; A/B/C=25-267.
DR   PDB; 2MSC; NMR; -; A/C=68-265.
DR   PDB; 2MSD; NMR; -; A/C=68-265.
DR   PDB; 2MSE; NMR; -; A/C=68-265.
DR   PDB; 2N5E; NMR; -; A/B=79-267.
DR   PDB; 3K2S; X-ray; -; A/B=25-267.
DR   PDB; 3R2P; X-ray; 2.20 A; A=25-208.
DR   PDB; 4V6M; EM; 7.10 A; A0/A1=68-267.
DR   PDBsum; 1AV1; -.
DR   PDBsum; 1GW3; -.
DR   PDBsum; 1GW4; -.
DR   PDBsum; 1ODP; -.
DR   PDBsum; 1ODQ; -.
DR   PDBsum; 1ODR; -.
DR   PDBsum; 2A01; -.
DR   PDBsum; 2MSC; -.
DR   PDBsum; 2MSD; -.
DR   PDBsum; 2MSE; -.
DR   PDBsum; 2N5E; -.
DR   PDBsum; 3K2S; -.
DR   PDBsum; 3R2P; -.
DR   PDBsum; 4V6M; -.
DR   ProteinModelPortal; P02647; -.
DR   SMR; P02647; -.
DR   BioGrid; 106832; 90.
DR   DIP; DIP-29619N; -.
DR   IntAct; P02647; 70.
DR   MINT; MINT-5000866; -.
DR   STRING; 9606.ENSP00000236850; -.
DR   ChEMBL; CHEMBL5984; -.
DR   iPTMnet; P02647; -.
DR   PhosphoSitePlus; P02647; -.
DR   BioMuta; APOA1; -.
DR   DMDM; 113992; -.
DR   DOSAC-COBS-2DPAGE; P02647; -.
DR   OGP; P02647; -.
DR   REPRODUCTION-2DPAGE; IPI00021841; -.
DR   REPRODUCTION-2DPAGE; P02647; -.
DR   SWISS-2DPAGE; P02647; -.
DR   UCD-2DPAGE; P02647; -.
DR   EPD; P02647; -.
DR   MaxQB; P02647; -.
DR   PaxDb; P02647; -.
DR   PeptideAtlas; P02647; -.
DR   PRIDE; P02647; -.
DR   DNASU; 335; -.
DR   Ensembl; ENST00000236850; ENSP00000236850; ENSG00000118137.
DR   Ensembl; ENST00000359492; ENSP00000352471; ENSG00000118137.
DR   Ensembl; ENST00000375320; ENSP00000364469; ENSG00000118137.
DR   Ensembl; ENST00000375323; ENSP00000364472; ENSG00000118137.
DR   GeneID; 335; -.
DR   KEGG; hsa:335; -.
DR   UCSC; uc001ppv.2; human.
DR   CTD; 335; -.
DR   DisGeNET; 335; -.
DR   GeneCards; APOA1; -.
DR   HGNC; HGNC:600; APOA1.
DR   HPA; CAB016778; -.
DR   HPA; HPA046715; -.
DR   MalaCards; APOA1; -.
DR   MIM; 105200; phenotype.
DR   MIM; 107680; gene+phenotype.
DR   MIM; 205400; phenotype.
DR   MIM; 604091; phenotype.
DR   neXtProt; NX_P02647; -.
DR   OpenTargets; ENSG00000118137; -.
DR   Orphanet; 425; Apolipoprotein A-I deficiency.
DR   Orphanet; 93560; Familial renal amyloidosis due to Apolipoprotein AI variant.
DR   Orphanet; 314701; Primary systemic amyloidosis.
DR   PharmGKB; PA49; -.
DR   eggNOG; ENOG410IWKR; Eukaryota.
DR   eggNOG; ENOG410YGQ6; LUCA.
DR   GeneTree; ENSGT00530000063081; -.
DR   HOGENOM; HOG000033998; -.
DR   HOVERGEN; HBG105708; -.
DR   InParanoid; P02647; -.
DR   KO; K08757; -.
DR   OMA; KDFATVY; -.
DR   OrthoDB; EOG091G0IA5; -.
DR   PhylomeDB; P02647; -.
DR   TreeFam; TF334458; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-1369062; ABC transporters in lipid homeostasis.
DR   Reactome; R-HSA-174800; Chylomicron-mediated lipid transport.
DR   Reactome; R-HSA-194223; HDL-mediated lipid transport.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-2168880; Scavenging of heme from plasma.
DR   Reactome; R-HSA-3000471; Scavenging by Class B Receptors.
DR   Reactome; R-HSA-3000480; Scavenging by Class A Receptors.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   ChiTaRS; APOA1; human.
DR   EvolutionaryTrace; P02647; -.
DR   GeneWiki; Apolipoprotein_A1; -.
DR   GenomeRNAi; 335; -.
DR   PMAP-CutDB; P02647; -.
DR   PRO; PR:P02647; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000118137; -.
DR   CleanEx; HS_APOA1; -.
DR   ExpressionAtlas; P02647; baseline and differential.
DR   Genevisible; P02647; HS.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0042627; C:chylomicron; IBA:GO_Central.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0034365; C:discoidal high-density lipoprotein particle; IEA:Ensembl.
DR   GO; GO:0005769; C:early endosome; TAS:Reactome.
DR   GO; GO:0030139; C:endocytic vesicle; IDA:BHF-UCL.
DR   GO; GO:0071682; C:endocytic vesicle lumen; TAS:Reactome.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:1903561; C:extracellular vesicle; IDA:UniProtKB.
DR   GO; GO:0034364; C:high-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0034366; C:spherical high-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034361; C:very-low-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034191; F:apolipoprotein A-I receptor binding; IPI:BHF-UCL.
DR   GO; GO:0034190; F:apolipoprotein receptor binding; IPI:BHF-UCL.
DR   GO; GO:0001540; F:beta-amyloid binding; IDA:BHF-UCL.
DR   GO; GO:0045499; F:chemorepellent activity; IDA:UniProtKB.
DR   GO; GO:0015485; F:cholesterol binding; IDA:BHF-UCL.
DR   GO; GO:0017127; F:cholesterol transporter activity; IMP:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0031072; F:heat shock protein binding; IPI:CAFA.
DR   GO; GO:0008035; F:high-density lipoprotein particle binding; IEA:Ensembl.
DR   GO; GO:0070653; F:high-density lipoprotein particle receptor binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0055102; F:lipase inhibitor activity; IEA:Ensembl.
DR   GO; GO:0031210; F:phosphatidylcholine binding; IBA:GO_Central.
DR   GO; GO:0060228; F:phosphatidylcholine-sterol O-acyltransferase activator activity; IDA:BHF-UCL.
DR   GO; GO:0005543; F:phospholipid binding; IDA:BHF-UCL.
DR   GO; GO:0005548; F:phospholipid transporter activity; IEA:Ensembl.
DR   GO; GO:0030325; P:adrenal gland development; IEA:Ensembl.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0043534; P:blood vessel endothelial cell migration; IEA:Ensembl.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IBA:GO_Central.
DR   GO; GO:0033344; P:cholesterol efflux; IDA:BHF-UCL.
DR   GO; GO:0042632; P:cholesterol homeostasis; IDA:BHF-UCL.
DR   GO; GO:0070508; P:cholesterol import; IMP:BHF-UCL.
DR   GO; GO:0008203; P:cholesterol metabolic process; IMP:BHF-UCL.
DR   GO; GO:0030301; P:cholesterol transport; IDA:MGI.
DR   GO; GO:0001935; P:endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0008211; P:glucocorticoid metabolic process; IEA:Ensembl.
DR   GO; GO:0034380; P:high-density lipoprotein particle assembly; IDA:BHF-UCL.
DR   GO; GO:0034384; P:high-density lipoprotein particle clearance; IC:BHF-UCL.
DR   GO; GO:0034375; P:high-density lipoprotein particle remodeling; IDA:BHF-UCL.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0019915; P:lipid storage; IEA:Ensembl.
DR   GO; GO:0042158; P:lipoprotein biosynthetic process; TAS:Reactome.
DR   GO; GO:0042157; P:lipoprotein metabolic process; IBA:GO_Central.
DR   GO; GO:0050919; P:negative chemotaxis; IDA:UniProtKB.
DR   GO; GO:0060354; P:negative regulation of cell adhesion molecule production; IDA:BHF-UCL.
DR   GO; GO:0002740; P:negative regulation of cytokine secretion involved in immune response; IDA:BHF-UCL.
DR   GO; GO:0034115; P:negative regulation of heterotypic cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IDA:BHF-UCL.
DR   GO; GO:0050713; P:negative regulation of interleukin-1 beta secretion; IDA:BHF-UCL.
DR   GO; GO:0060192; P:negative regulation of lipase activity; IEA:Ensembl.
DR   GO; GO:0060761; P:negative regulation of response to cytokine stimulus; IDA:BHF-UCL.
DR   GO; GO:0010804; P:negative regulation of tumor necrosis factor-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0010903; P:negative regulation of very-low-density lipoprotein particle remodeling; IDA:BHF-UCL.
DR   GO; GO:0031102; P:neuron projection regeneration; IBA:GO_Central.
DR   GO; GO:0018206; P:peptidyl-methionine modification; IDA:UniProtKB.
DR   GO; GO:0014012; P:peripheral nervous system axon regeneration; IEA:Ensembl.
DR   GO; GO:0006656; P:phosphatidylcholine biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0033700; P:phospholipid efflux; IDA:BHF-UCL.
DR   GO; GO:0055091; P:phospholipid homeostasis; IDA:BHF-UCL.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0010873; P:positive regulation of cholesterol esterification; IDA:BHF-UCL.
DR   GO; GO:0045723; P:positive regulation of fatty acid biosynthetic process; IBA:GO_Central.
DR   GO; GO:0051345; P:positive regulation of hydrolase activity; IDA:BHF-UCL.
DR   GO; GO:0051006; P:positive regulation of lipoprotein lipase activity; IBA:GO_Central.
DR   GO; GO:0035025; P:positive regulation of Rho protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IDA:UniProtKB.
DR   GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IDA:UniProtKB.
DR   GO; GO:0010898; P:positive regulation of triglyceride catabolic process; IBA:GO_Central.
DR   GO; GO:0018158; P:protein oxidation; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IDA:BHF-UCL.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; TAS:Reactome.
DR   GO; GO:0032489; P:regulation of Cdc42 protein signal transduction; IDA:BHF-UCL.
DR   GO; GO:0030300; P:regulation of intestinal cholesterol absorption; IBA:GO_Central.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0043691; P:reverse cholesterol transport; IMP:BHF-UCL.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   GO; GO:0019433; P:triglyceride catabolic process; IBA:GO_Central.
DR   GO; GO:0070328; P:triglyceride homeostasis; IDA:BHF-UCL.
DR   GO; GO:0051180; P:vitamin transport; IMP:AgBase.
DR   InterPro; IPR000074; ApoA_E.
DR   Pfam; PF01442; Apolipoprotein; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Amyloid; Amyloidosis; Atherosclerosis;
KW   Cholesterol metabolism; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Glycation; Glycoprotein; HDL; Lipid metabolism;
KW   Lipid transport; Lipoprotein; Neuropathy; Oxidation; Palmitate;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat; Secreted;
KW   Signal; Steroid metabolism; Sterol metabolism; Transport.
FT   SIGNAL        1     18       {ECO:0000269|PubMed:6328445,
FT                                ECO:0000269|PubMed:6409108}.
FT   CHAIN        19    267       Proapolipoprotein A-I.
FT                                /FTId=PRO_0000425323.
FT   CHAIN        25    267       Apolipoprotein A-I.
FT                                /FTId=PRO_0000001939.
FT   CHAIN        25    266       Truncated apolipoprotein A-I.
FT                                /FTId=PRO_0000001940.
FT   REPEAT       68     89       1.
FT   REPEAT       90    111       2.
FT   REPEAT      112    122       3; half-length.
FT   REPEAT      123    144       4.
FT   REPEAT      145    166       5.
FT   REPEAT      167    188       6.
FT   REPEAT      189    210       7.
FT   REPEAT      211    232       8.
FT   REPEAT      233    243       9; half-length.
FT   REPEAT      244    267       10.
FT   REGION       68    267       10 X approximate tandem repeats.
FT   MOD_RES     110    110       Methionine sulfoxide.
FT                                {ECO:0000269|PubMed:12576517}.
FT   MOD_RES     136    136       Methionine sulfoxide.
FT                                {ECO:0000269|PubMed:12576517}.
FT   CARBOHYD    263    263       N-linked (Glc) (glycation) lysine.
FT   VARIANT      27     27       P -> H (in Munster-3C;
FT                                dbSNP:rs121912720).
FT                                /FTId=VAR_000605.
FT   VARIANT      27     27       P -> R (in dbSNP:rs121912720).
FT                                {ECO:0000269|PubMed:2512329}.
FT                                /FTId=VAR_000606.
FT   VARIANT      28     28       P -> R (in Munster-3B;
FT                                dbSNP:rs121912721).
FT                                {ECO:0000269|PubMed:2512329}.
FT                                /FTId=VAR_000607.
FT   VARIANT      34     34       R -> L (in Baltimore; dbSNP:rs28929476).
FT                                {ECO:0000269|PubMed:2108924}.
FT                                /FTId=VAR_000608.
FT   VARIANT      50     50       G -> R (in AMYL8; also found in a family
FT                                with amyloid polyneuropathy-nephropathy
FT                                Iowa; dbSNP:rs28931574).
FT                                {ECO:0000269|PubMed:2123470,
FT                                ECO:0000269|PubMed:3142462,
FT                                ECO:0000269|PubMed:8208902}.
FT                                /FTId=VAR_000609.
FT   VARIANT      61     61       A -> T (in dbSNP:rs12718465).
FT                                {ECO:0000269|PubMed:15108119}.
FT                                /FTId=VAR_025445.
FT   VARIANT      84     84       L -> R (in AMYL8; dbSNP:rs121912724).
FT                                {ECO:0000269|PubMed:1502149}.
FT                                /FTId=VAR_000610.
FT   VARIANT      92     92       T -> I (polymorphism; confirmed at
FT                                protein level; dbSNP:rs766422306).
FT                                {ECO:0000269|PubMed:12966036,
FT                                ECO:0000269|PubMed:22028381}.
FT                                /FTId=VAR_017017.
FT   VARIANT     113    113       D -> E (in dbSNP:rs150243849).
FT                                {ECO:0000269|PubMed:2111322}.
FT                                /FTId=VAR_000611.
FT   VARIANT     119    119       A -> D (in Hita).
FT                                /FTId=VAR_000612.
FT   VARIANT     126    126       D -> H (in dbSNP:rs5077).
FT                                /FTId=VAR_016189.
FT   VARIANT     127    127       D -> N (in Munster-3A).
FT                                /FTId=VAR_000613.
FT   VARIANT     131    131       K -> M (in dbSNP:rs4882).
FT                                {ECO:0000269|PubMed:2111322}.
FT                                /FTId=VAR_000615.
FT   VARIANT     131    131       Missing (in Marburg/Munster-2).
FT                                /FTId=VAR_000614.
FT   VARIANT     132    132       W -> R (in Tsushima).
FT                                /FTId=VAR_000616.
FT   VARIANT     134    134       E -> K (in Fukuoka).
FT                                {ECO:0000269|PubMed:2107878}.
FT                                /FTId=VAR_000617.
FT   VARIANT     160    160       E -> K (in Norway; dbSNP:rs121912718).
FT                                {ECO:0000269|PubMed:6432779}.
FT                                /FTId=VAR_000618.
FT   VARIANT     163    163       E -> G (in dbSNP:rs758509542).
FT                                {ECO:0000269|PubMed:2111322}.
FT                                /FTId=VAR_000619.
FT   VARIANT     167    167       P -> R (in Giessen; dbSNP:rs121912719).
FT                                {ECO:0000269|PubMed:6489332}.
FT                                /FTId=VAR_000620.
FT   VARIANT     168    168       L -> R (in Zaragoza).
FT                                {ECO:0000269|Ref.56}.
FT                                /FTId=VAR_000621.
FT   VARIANT     171    171       E -> V. {ECO:0000269|PubMed:2111322}.
FT                                /FTId=VAR_000622.
FT   VARIANT     173    173       R -> S (in Boston; no evidence of
FT                                association with premature coronary heart
FT                                disease; associated with decreased levels
FT                                of HDL cholesterol; associated with
FT                                decreased serum cellular cholesterol
FT                                efflux; associated with decreased
FT                                lecithin-cholesterol acyltransferase
FT                                (LCAT) activity).
FT                                {ECO:0000269|PubMed:26073399}.
FT                                /FTId=VAR_074073.
FT   VARIANT     180    180       V -> E (in Oita; 60% of normal apoA-I and
FT                                normal HDL cholesterol levels; rapidly
FT                                cleared from plasma; dbSNP:rs121912727).
FT                                {ECO:0000269|PubMed:9514407}.
FT                                /FTId=VAR_021362.
FT   VARIANT     184    184       R -> P (in dbSNP:rs5078).
FT                                /FTId=VAR_014609.
FT   VARIANT     189    189       P -> R (in dbSNP:rs121912722).
FT                                {ECO:0000269|PubMed:2512329}.
FT                                /FTId=VAR_000623.
FT   VARIANT     197    197       R -> C (in Milano; no evidence of
FT                                association with premature vascular
FT                                disease; associated with decreased HDL
FT                                levels and moderate increase in
FT                                triglycerides; allows the formation of
FT                                disulfide-linked homodimers via the
FT                                introduced cysteine; assembles properly
FT                                in HDL; alters protein structure; has no
FT                                tendency to form fibrils and aggregates;
FT                                dbSNP:rs28931573).
FT                                {ECO:0000269|PubMed:24755625,
FT                                ECO:0000269|PubMed:6401735}.
FT                                /FTId=VAR_000624.
FT   VARIANT     222    222       E -> K (in Munster-4; dbSNP:rs121912717).
FT                                {ECO:0000269|PubMed:2111322}.
FT                                /FTId=VAR_000625.
FT   CONFLICT     32     32       W -> P (in Ref. 25; AA sequence).
FT                                {ECO:0000305}.
FT   HELIX        33     42       {ECO:0000244|PDB:3R2P}.
FT   HELIX        45     59       {ECO:0000244|PDB:3R2P}.
FT   HELIX        61     65       {ECO:0000244|PDB:3R2P}.
FT   STRAND       69     73       {ECO:0000244|PDB:2A01}.
FT   HELIX        80     88       {ECO:0000244|PDB:3R2P}.
FT   HELIX        93    158       {ECO:0000244|PDB:3R2P}.
FT   TURN        159    164       {ECO:0000244|PDB:3R2P}.
FT   HELIX       166    203       {ECO:0000244|PDB:3R2P}.
FT   TURN        212    214       {ECO:0000244|PDB:2A01}.
FT   STRAND      215    217       {ECO:0000244|PDB:2A01}.
FT   HELIX       220    237       {ECO:0000244|PDB:2A01}.
FT   STRAND      238    240       {ECO:0000244|PDB:2A01}.
FT   HELIX       243    266       {ECO:0000244|PDB:2A01}.
SQ   SEQUENCE   267 AA;  30778 MW;  1A28B8366E620310 CRC64;
     MKAAVLTLAV LFLTGSQARH FWQQDEPPQS PWDRVKDLAT VYVDVLKDSG RDYVSQFEGS
     ALGKQLNLKL LDNWDSVTST FSKLREQLGP VTQEFWDNLE KETEGLRQEM SKDLEEVKAK
     VQPYLDDFQK KWQEEMELYR QKVEPLRAEL QEGARQKLHE LQEKLSPLGE EMRDRARAHV
     DALRTHLAPY SDELRQRLAA RLEALKENGG ARLAEYHAKA TEHLSTLSEK AKPALEDLRQ
     GLLPVLESFK VSFLSALEEY TKKLNTQ
//
